^
Association details:
| Biomarker: | STEAP1 expression |
|---|---|
| Cancer: | Prostate Cancer |
| Drug: | xaluritamig (AMG 509) (CD3 agonist, STEAP1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Abstract DDT02-03: AMG 509: A novel, humanized, half-Life extended, bispecific STEAP1 × CD3 T cell recruiting XmAb® 2+1 antibody
Published date:
04/28/2020
Excerpt:
...we found membranous STEAP1 expression by IHC in 80% of primary prostate cancer tumors (n = 80) and moderate to high expression in 83% of metastatic prostate cancer lesions (n = 181) and 77% of bone metastases (n = 31)….AMG 509 triggered potent T cell-redirected lysis of STEAP1-positive cancer cells, with a median EC50 of 18.9 pM across 17 different STEAP1-expressing prostate, EWS, gastric, and melanoma cancer cell lines. AMG 509 was 50-fold more potent in inducing the redirected lysis of C4-2B prostate cancer cells in vitro than an XmAb® molecule with a single anti-STEAP1 Fab domain....AMG 509 is a potent and specific first-in-class T cell-recruiting antibody for the treatment of STEAP1-positive malignancies.
DOI:
10.1158/1538-7445.AM2020-DDT02-03
